Detalles de la búsqueda
1.
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
Ann Hematol
; 102(6): 1395-1408, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37119314
2.
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
Am J Hematol
; 97(4): 421-430, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015312
3.
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Br J Haematol
; 193(5): 915-921, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33782950
4.
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
Eur J Haematol
; 107(6): 617-623, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34418168
5.
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells.
Haematologica
; 105(8): 2095-2104, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582541
6.
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
Blood
; 129(17): 2384-2394, 2017 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28122740
7.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Lancet Oncol
; 19(6): 747-757, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29735299
8.
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.
Blood
; 128(23): 2683-2693, 2016 12 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27621309
9.
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.
Haematologica
; 103(3): 447-455, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29284680
10.
Prospective evaluation of a combination of fungal biomarkers for the diagnosis of invasive fungal disease in high-risk haematology patients.
Mycoses
; 61(9): 623-632, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29577474
11.
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
Proc Natl Acad Sci U S A
; 112(34): 10786-91, 2015 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-26261316
12.
The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.
Eur J Haematol
; 98(4): 398-406, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28009456
13.
Forced expression of human macrophage colony-stimulating factor in CD34+ cells promotes monocyte differentiation in vitro and in vivo but blunts osteoclastogenesis in vitro.
Eur J Haematol
; 98(5): 517-526, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28160330
14.
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
Eur J Haematol
; 98(1): 57-66, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27428357
15.
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.
Ann Intern Med
; 165(3): 161-6, 2016 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27295519
16.
Regulation and Function of Lentiviral Vector-Mediated TCIRG1 Expression in Osteoclasts from Patients with Infantile Malignant Osteopetrosis: Implications for Gene Therapy.
Calcif Tissue Int
; 99(6): 638-648, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27541021
17.
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
Eur J Haematol
; 97(4): 387-92, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26833713
18.
In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
Ther Drug Monit
; 38(2): 230-8, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26693810
19.
Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.
Int J Mol Sci
; 17(5)2016 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-27136541
20.
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Br J Haematol
; 169(5): 683-8, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25817799